Back Bay Life Science Report
ചാനൽ വിവരങ്ങൾ
Back Bay Life Science Report
Back Bay Life Science Advisors brings you expert insights from our advisors and investment bankers in the world of BioPharma & MedTech. On this podcast, you’ll hear from our experts in life science development, commercialization, and investment banking, scientific investigators, biotech and medtech...
സമീപകാല എപ്പിസോഡുകൾ
32 എപ്പിസോഡുകൾ
A Capital Markets Outlook for 2025: 2024, A Year in Review
In this DNB//Back Bay Healthcare Capital Markets podcast episode, Jim Cirenza, Head of Fixed Income and Equities at DNB, Kristoffer Braaten, Director...
The Optimism of Bispecific Antibodies
The topic of bispecific antibodies has been an area of interest in the pharma space for a long time now. The recent news of the notable late-stage dat...
Dynamics in Healthcare Focused Markets
In this DNB//Back Bay Healthcare Capital Markets Episode, Vasilios Kofitsas, Partner and Managing Director at Back Bay Life Science Advisors speaks wi...
From NASH to MASH: Current Market Dynamics in Hepatology
After a summer away from podcasting, Back Bay Life Science Advisors’ Dr. Pete Bak and Christian Thienel are back on the mic to discuss current market...
Key Considerations for a US Healthcare IPO
In this DNB//Back Bay Healthcare Capital Markets podcast episode, learn about the key considerations, mechanics and timelines of going public on a US...
Drug Development in Obesity
Guests: Pete Bak and Christian Thienel
Length: 27 minutes
In this episode of The Life Science Report, Dr. Pete Bak and Bac...
The Current Dynamics in Capital Markets
Welcome to another episode with the DNB//Back Bay Partnership for Healthcare.
In this episode Jonathan Gertler, Back Bay CEO and Managing Partne...
Vaccine Developments 2024: A Podcast Discussion on Latest Vaccine Technology and Ongoing Clinical Developments
Guests: Pete Bak and Christian Thienel
Length: 37 minutes
With the advent of COVID-19 in 2020 and 2021, we saw a tremendou...
Trends and Investment Activity in Radiopharmaceuticals and Psychedelics
A Podcast Discussion on the Trends and Investment Activity in Radiopharmaceuticals and Psychedelics
Guests: Pete Bak and Christian Thienel
...
Vertex’s Exa-cel to Biogen and Sage’s Zurzuvae: Notable Product Approvals of 2023
As we move into 2024, Back Bay’s strategic advisors summarize key product approvals from three classes and indications over this past year, including...
Monthly Roundup of News from Healthcare Development
In our latest podcast, Back Bay Life Science Advisors focused on the chronic and rare disease development of kidney disease. Recently, there have been...
The Current and Future Landscape of Healthcare IPO Markets
With the DNB//Back Bay Partnership for Healthcare
In the current markets, Healthcare continues to rally as the second-largest industry behind te...
The Heart of the Matter: Behind the Renewed Interest in Cardiovascular Disease
A conversation on the rising trends in the cardiology space
Cardiology has historically been a cornerstone of large pharmaceutical portfolios. T...
The Transactional Landscape Of ADCs: The Powerhouse of Antibody Drug Conjugates
In this episode, Dr. Peter Bak is joined by Trent Gordon and Dr. Mavra Nasir as they discuss their Bioprocess Online article published earlier this ye...
Investing in Health Tech & Digital Medicine: Expert Talk with Mikaela Odlander & Edward Kliphuis
The world of health tech has changed dramatically since decades ago when physicians had to endure 11 keystrokes to prescribe a single aspirin. These d...
Contingencies for Biopharma, Medtech Deal Planning in a Down Market
For biopharma and medtech companies developing new treatments, capital for advancement and growth is invariably dependent on strategic preparation, di...
Gene Editing to Cross-Species Transplantation: The Most Compelling Healthcare Stories of 2022
In our first podcast episode of 2023, Back Bay’s strategic advisors summarize some of the most compelling healthcare development stories from 2022. Fr...
Preparing BioPharma and Medtech Companies for Public Listing - Back Bay Life Science Advisors and Nasdaq Nordic
For biopharma and medtech companies, the decision to go public is predicated on many business decisions—what kind of capital can be raised? Is our inv...
The Promising Field of Targeted Protein Degraders (TPDs)
with Back Bay Life Science Advisors’ Dr. Peter Bak and Dr. Mavra Nasir
Dr. Mavra Nasir recently published a thought piece in Biopharma Dealmaker...
Early Market Access and Pricing with Pete Bak, Christian Thieniel and Brendan Wang
This is the first episode in our podcast series of Q&As on biopharma and medtech development—directly from active developers. Our podcast listeners, i...
Living Medicines – Current and Future Uses of Car T Cells with Peter Bak, PhD and Mike Bogetofte Barnkob, MD, PhD
In this episode of Back Bay’s industry podcast, The Life Science Report, Dr. Peter Bak is joined by Mike Bogetofte Barnkob, a doctor with the Departme...
The Evolving Regulatory Framework for Novel Medicines in the EU
Biopharma companies looking to establish a footprint in Europe face country-specific decision-making processes. The health technology assessments (HTA...
The Commercial Potential of Optogenetic Therapies
Fifteen years ago, scientists discovered optogenetics, a technique of using light to stimulate light-sensitive receptors in order to turn brain cells...
The Latest on Antibiotic Development, Back Bay Life Science Advisors with Antabio
Antibiotics act as a safety net for all of healthcare. They make medical procedures such as surgeries, childbirth and cancer treatments possible, but...
Best Practices for Successful Sell-Side Licensing, Partnering and M&A
Despite the heavy influx of capital over the past years, medtech or biopharma sell-side assignments can still be ripe with challenges. In this episode...
Cell and Gene Therapy Investment Trends
Cell and gene therapies are currently among the hottest investments in the biotech space, both in the public and private markets. In this episode, Bac...
MedTech Investing with Paul LaViolette of SV Health Investors and Jonathan P. Gertler, MD, Back Bay Life Science Advisors and BioVentures Medtech Funds
“I have a deep belief that medtech and healthtech are going to carry us forward to markedly improve delivery and quality of healthcare.” - Jonathan P...
Remote Patient Monitoring
One of the unexpected outcomes of the COVID-19 pandemic has been the rapid and widespread uptake of remote patient monitoring. Just ahead of the pande...
New Drug Pricing and Market Access
In this episode of our life science industry podcast, Dr. Peter Bak sits down with Brendan Wang and Christian Thienel of Back Bay Life Science Advisor...
The Question of Investment in Antimicrobials
In this episode Jonathan Gertler, Back Bay’s CEO and Managing Partner, sits down with Dr. Peter Bak, Managing Director at Back Bay, to discuss Dr. Bak...
Life Science SPACs: A Forward Look at this Evolving Asset Class
Welcome to Episode #2 of The Life Science Report. In this week’s episode Jonathan Gertler, Back Bay’s CEO and Managing Partner, is joined by Gregory B...
Gene Therapies: What’s to Come as The Industry Moves Forward
Welcome to Episode 1 of The Life Science Report. In this episode our host, Dr. Peter Bak, sits down with Brendan Wang and Kyle O’Neil of Back Bay Life...